NASDAQ:CDAK • US1920101060
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CODIAK BIOSCIENCES INC (CDAK).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-07 | Goldman Sachs | Maintains | Neutral |
| 2022-09-01 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-07-05 | Goldman Sachs | Maintains | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-02-22 | Wedbush | Maintains | Outperform |
| 2022-02-11 | Goldman Sachs | Initiate | Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 390K | 2.92M 648.72% | 22.935M 685.45% | 27.589M 20.29% | 2.674M -90.31% | 2.394M -10.47% | 897.6K -62.51% | -100.00% | |
| EBITDA YoY % growth | -77.38M -111.19% | -86.56M -11.86% | -64.208M 25.82% | -50.678M 21.07% | -62.271M -22.88% | -77.741M -24.84% | N/A | N/A | |
| EBIT YoY % growth | -80.15M -108.89% | -90.92M -13.44% | -69.549M 23.51% | -51.347M 26.17% | -64.246M -25.12% | -79.538M -23.80% | -93.415M -17.45% | -110.798M -18.61% | |
| Operating Margin | -20,551.28% | -3,113.70% | -303.24% | -186.11% | -2,402.63% | -3,322.37% | -10,407.16% | N/A | |
| EPS YoY % growth | N/A | N/A | -3.21 83.10% | -1.89 41.06% | -1.25 33.83% | -0.96 23.15% | -0.86 10.95% | -0.92 -7.14% |
All data in USD
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.35 53.14% | -0.33 8.39% | -0.30 -0.87% | -0.30 49.86% | -0.24 29.41% | -0.27 19.59% | -0.28 8.99% | -0.28 6.90% | -0.28 -12.50% |
| Revenue Q2Q % growth | 691.897K -91.01% | 1.038M -91.83% | 1.038M -92.10% | 1.038M 98.85% | 1.798M 159.87% | 1.798M 73.22% | 1.798M 73.22% | 1.798M 73.22% | 1.798M |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.481M 6.97% | -16.014M -94.09% | -16.014M -128.22% | -16.524M 2.16% | N/A | N/A | N/A | N/A | N/A |
All data in USD
7 analysts have analysed CDAK and the average price target is 9.18 USD. This implies a price increase of 16005.26% is expected in the next year compared to the current price of 0.057.
CODIAK BIOSCIENCES INC (CDAK) will report earnings on 2023-05-03.
The consensus EPS estimate for the next earnings of CODIAK BIOSCIENCES INC (CDAK) is -0.35 USD and the consensus revenue estimate is 691.90K USD.
The number of analysts covering CODIAK BIOSCIENCES INC (CDAK) is 7.